JAK inhibitors in lichen planus: a review of pathogenesis and treatments

被引：38

作者：

Motamed-Sanaye, Ali ^{[1
,2
]}

Khazaee, Yasaman Fatemeh ^{[3
]}

Shokrgozar, Motahareh ^{[4
]}

Alishahi, Maryam ^{[4
]}

Ahramiyanpour, Najmeh ^{[5
]}

Amani, Maliheh ^{[6
]}

机构：

[1] Gonabad Univ Med Sci, Fac Med, Infect Dis Res Ctr, Student Res Comm, Gonabad, Iran

[2] Gonabad Univ Med Sci, Bohlool Hosp, Clin Res Dev Unit, Gonabad, Iran

[3] Gonabad Univ Med Sci, Fac Med, Dept Pediat, Gonabad, Iran

[4] Gonabad Univ Med Sci, Fac Med, Gonabad, Iran

[5] Kerman Univ Med Sci, Afzalipour Hosp, Afzalipour Fac Med, Dept Dermatol, Kerman, Iran

[6] Gonabad Univ Med Sci, Fac Med, Dept Dermatol, Gonabad, Iran

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2022年 / 33卷 / 08期

关键词：

Lichen planus; JAK inhibitors; JAK pathway; tofacitinib; barcitinib; upadacitinib; ruxolitinib; CELLS;

D O I：

10.1080/09546634.2022.2116926

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Lichen planus (LP) is an auto-inflammatory skin disorder identified by a presence of T-cell lymphocytes at the dermal-epidermal junction. It is hypothesized that the INF-gamma/CXCL10 axis fulfills a major role in the onset and persistence of chronic inflammation in LP. Since Janus kinases (JAKs) are involved in the transduction of INF-gamma signals, they may be good targets for LP treatment. Several case reports and case series described the safety and efficacy of upadacitinib (2 articles), tofacitinib (6 articles), baricitinib (4 articles), and Ruxolitinib (1 Article) in the treatment of LP variants. The predominant variants that JAK inhibitors improved were lichen planopilaris, nail LP, and erosive LP. Considering the role of the JAK pathway in LP pathogenesis and the evidence provided by these reports, it seems JAK inhibitors would be effective therapeutic agents for LP treatment. Hence, these agents should be trialed and evaluated further.

引用

页码：3098 / 3103

页数：6

共 32 条

[1] Treatment of Oral Erosive Lichen Planus With Upadacitinib [J].